Protocols
37 protocol(s) meet the specified criteria
Disease Site: Lung
Protocol No.TitleStatus
11-0992Lung Cancer Surgery: Decisions Against Life Saving Care - The InterventionOpen
11-1474Accountability for Cancer Care through Undoing Racism and Equity (ACCURE)Open
1990-2012Metastasis 1990-2012 - Molecular Predictors of Metastasis in Patients with CancerOpen
8273-CL-0102An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects with Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) MutationsOpen
A081105-CIRBRandomized Double Blind Placebo Controlled Study of Erlotinib or Placebo In Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) Open
A151216-CIRBAdjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)Open
A8081001Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-Met/HGRF Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer Open
AMC-083Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies A Trial of the AIDS Malignancy Consortium (AMC)Open
CALGB30605A Phase II Study of Induction Chemotherapy followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer Open (affiliates only)
CALGB30607Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer Open (affiliates only)
CALGB30610Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and EtoposideOpen (affiliates only)
CALGB30704A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC #736511, IND #74019) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer Open (affiliates only)
CALGB79803Phase III Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I Non-Small Cell Lung CancerOpen (affiliates only)
D6410C00001A Phase I, First-Time-in Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally in Subjects with Solid Tumor CancerOpen
E4512-CIRBA Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion ProteinOpen
G1T28-02Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Extensive-Stage small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin ChemotherapyOpen
GO29322A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered with Ipilimumab, Interferon-Alpha, or Other Immune-Modulating Therapies in Patients with Locally Advanced or Metastatic Solid TumorsOpen
LCCC1123Phase II Study Of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR-TKI Open
LCCC1210Tolerability of weekly nab-paclitaxel as second line treatment for elderly patients with advanced lung cancerOpen
LCCC1337Evaluation of the Lung nodule Sensitivity of Stationary Chest Tomosynthesis versus Chest Radiographs in PatientsOpen
LCCC1425Molecular Drivers of Lung Squamous Cell Cancer Lymph Node Metastasis. Open
LCCC1516A Randomized, Non-comparative Three Arm Phase II Trial of Sequential Consolidation with Pembrolizumab followed by Nab-paclitaxel, Sequential Consolidation with Nab-paclitaxel followed by Pembrolizumab and Concurrent Consolidation with Nab-paclitaxel and Pembrolizumab after Standard First-Line Induction Chemotherapy in Advanced NSCLCOpen
LCCC1535Understanding Treatment Decision-making and Psychological Distress in Patients with Advanced CancerOpen
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
LCCC1540Prospective Evaluation of Patient-Reported Xerostomia After Whole Brain Radiation.Open
LCCC1623Interviewing cancer patients and caregivers about using symptom questionnaires to improve quality of cancer careOpen
M14-360A Phase I Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and tolerability of Veliparib in Combination with Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects with Stage III Non-Small Cell Lung Cancer (NSCLC)Open
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
MM-398-01-01-02A Phase 1 Study in Patients Treated with MM-398 (Nanoliposomal Irinotecan, nal-IRI,) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to TreatmentOpen
MUSC001A multi-center trial comparing standard 22-gauge and 22-gauge ProCore needles for endobronchial ultrasoundOpen
NC-6004-004AA Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) plus Gemcitabine in Patients with Advanced Solid Tumors or Non-Small Cell Lung Cancer, Biliary Tract, and Bladder CancerOpen
PCRC-14-07Caregiver-­‐guided pain management training in palliative careOpen
PERCEPTA-R-1Prospective Registry to Evaluate Percepta Bronchial Genomic Classifier Patient Data: The PERCEPTA RegistryOpen
RC1126Randomized Phase II Trial of Erlotinib Alone or In Combination with Bevacizumab in Patients With Non-Small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor MutationsOpen
TRT-001A Multi-center Study of hTERT Immunotherapy Alone or in Combination with IL-12 DNA Followed by Electroporation in Adults with Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard TherapyOpen
TSP0147Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction PatientsOpen